

CANADA

PROVINCE OF QUEBEC  
DISTRICT OF MONTREAL

NO: 500-06-000484-093

(Class Action)  
SUPERIOR COURT

---

JANIE GUINDON

and

GENEVIÈVE GLADU

and

JULIEN LEBOEUF

Plaintiffs

v.

BAYER INC.

Defendant

---

**RE-RE-AMENDED MOTION TO AUTHORIZE THE BRINGING OF A CLASS  
ACTION & TO ASCRIBE THE STATUS OF REPRESENTATIVES  
(Art. 1002 C.C.P. and following)**

---

**TO THE HONOURABLE JUSTICE OF THE SUPERIOR COURT, GUYLÈNE  
BEAUGÉ, SITTING IN AND FOR THE DISTRICT OF MONTREAL, YOUR  
PLAINTIFFS STATE AS FOLLOWS:**

**I. GENERAL PRESENTATION**

**A) The Action**

1. Plaintiffs wish to institute a class action on behalf of the following group, of which they are members, namely:

«All persons residing in Quebec who were prescribed and ingested the drugs YASMIN and/or YAZ, from the respective introductions of these drugs into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of YAZ) and the date of November 30, 2011 and their successors, assigns, family members, and dependants or any other group to be determined by the Court.»

## B) The Defendant

2. [...];
3. Bayer Inc. ("Bayer") is a Federal corporation with its head office in Etobicoke, Ontario. Bayer is a wholly owned subsidiary of Bayer A.G. Bayer is involved in marketing, distribution and sale of healthcare and material science products and has a principal establishment in Montreal, the whole as appears from the Information sheet on the Registraire des entreprises du Quebec, a copy of which is produced herewith as **Exhibit P-1**. At all material times, Bayer was engaged in the business of designing, manufacturing, developing the formula for, preparing, processing, inspecting, testing, packaging, promoting, marketing, distributing, labelling, and/or selling for a profit, either directly or indirectly through an agent, affiliate, predecessor or subsidiary, Yasmin and Yaz in Canada. The development of Yasmin and Yaz for sale in Canada, the conduct of clinical studies, the preparation of regulatory applications, the maintenance of regulatory records, the labelling and promotional activities regarding Yasmin and Yaz, and other actions central to the allegations of this lawsuit, were undertaken by Bayer in Quebec and elsewhere;
4. [...];
5. [...];
- 5.1 [...];
- 5.2 [...];
- 5.3 [...];
- 5.4 [...];
- 5.5 [...];
- 5.6 [...];
6. [...];

## C) The Situation

- 6.1 Yasmin and Yaz are oral contraceptives manufactured by Bayer, indicated in Canada for the prevention of pregnancy and treatment of moderate acne vulgaris in women (16 years of age or older for Yasmin and 14 years of age or older for Yaz) who have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche

the whole as appears from the product monographs, copies of which are produced herewith as **Exhibit P-2** (Yasmin) and **Exhibit P-3** (Yaz);

- 6.2 Yasmin was approved by Health Canada on December 10<sup>th</sup>, 2004 and Yaz was approved by Health Canada in late 2008;
- 6.3 Yasmin and Yaz are two (2) of the largest selling contraceptives worldwide. Yasmin was the third most prescribed oral contraceptive in Canada in 2008. Worldwide sales of Yasmin and Yaz in 2008 were approximately \$1.8 billion;
7. Yasmin and Yaz are combination oral contraceptives (“COCs”), meaning that they contain an estrogen component and a progestin component. Together, these steroidal components work together in COCs to suppress ovulation, fertilization, and implantation and thus prevent pregnancy;
8. [...];
9. The estrogen component in Yasmin and Yaz is known generically as ethinyl estradiol. The progestin component is known as drospirenone. Yasmin contains 0.03 milligrams of ethinyl estradiol and Yaz contains 0.02 milligrams of ethinyl estradiol. Both drugs contain 3 milligrams of drospirenone;
10. The difference between Yaz / Yasmin and other birth control pills on the market is that drospirenone is a new type of progestin and is unlike any other on the market. Drospirenone is considered to be a fourth-generation progestin;

### **C.1) THE RISKS**

11. Since Yasmin and Yaz contain the progestin drospirenone, they present additional health risks not associated with other birth control pills;
  - 11.1 Drospirenone is a spironolactone analog and can cause elevation of potassium levels (hyperkalemia) and a decrease in sodium levels (hyponatremia) due to its potassium-sparing diuretic effects. Potassium is a key control in the electrical system of the heart and elevated levels can cause arrhythmias which can lead to stroke, deep vein thrombosis, pulmonary embolism, heart attack, or sudden death. Because drospirenone can act like a diuretic, it can also cause dehydration which can lead to kidney stones and gall bladder disease and/or removal;
  - 11.2 Because drospirenone is used as the progestin component, the risk of suffering from stroke, deep vein thrombosis, pulmonary embolism, heart attack, or gall bladder disease and/or removal, is substantially higher

among women who use Yasmin or Yaz compared to women who use second generation oral contraceptives with a first or second generation progestin component;

12.[...];

13.[...];

14.[...];

15.[...];

16. Further, because of the combination of estrogen and drospirenone found in Yaz and Yasmin, they can affect a woman's hormonal level in a way that previous classes of birth control pills did not, and can also cause bouts of severe anxiety, depression and other mental health issues;

16.1 During the brief time that Yasmin and Yaz have been sold, hundreds of reports of injury and death have been reported to health regulatory agencies in association with these products;

16.2 On or about April 13<sup>th</sup> 2002, the British Medical Journal reported that the Dutch College of General Practitioners recommended that second generation birth control pills be prescribed in lieu of Yasmin, due to the adverse event reports of forty (40) women who experienced venous thrombosis associated with their use of Yasmin, the whole as appears from the British Medical Journal article dated April 13<sup>th</sup>, 2002, a copy of which is produced herewith as **Exhibit P-4**;

16.3 On or about February 1<sup>st</sup>, 2003, the British Medical Journal published a paper entitled *Thromboembolism Associated with the New Contraceptive Yasmin*. This paper stated that the Dutch spontaneous reporting system for adverse drug reactions received five (5) reports of thromboembolism (including death) as a suspected adverse drug reaction to the new oral contraceptive Yasmin, the whole as appears from the British Medical Journal paper dated February 1<sup>st</sup>, 2003, a copy of which is produced herewith as **Exhibit P-5**;

16.4 On or about August 13<sup>th</sup> 2009, the British Medical Journal published a study stating that oral contraceptives containing drospirenone (Yasmin and Yaz) carry a 6.3 times increased risk of deep vein thrombosis or pulmonary embolism. When compared to women taking some other type of birth control, the increased risk was nearly four (4) times more among users of Yasmin and Yaz, the whole as appears from the British Medical Journal study, a copy of which is produced herewith as **Exhibit P-6**;



- 16.5 Notwithstanding the well documented safety hazards associated with using Yasmin and Yaz, Bayer failed to conduct meaningful post-market surveillance;
- 16.6 Bayer aggressively marketed Yasmin and Yaz without adequately disclosing the increased safety hazards associated with using Yasmin and Yaz as compared to second generation oral contraceptives;
- 16.7 At all material times, Bayer knew or should have known that the risks of using Yasmin and/or Yaz included severe and life threatening complications and side effects;
- 16.8 At all material times, Bayer, through its servants and agents, failed to adequately warn physicians and consumers, including the Plaintiffs and putative class members, that the risk of developing adverse events including stroke, deep vein thrombosis, pulmonary embolism, heart attack, gall bladder disease and/or removal, liver failure, kidney failure, severe anxiety, depression or sudden death associated with using Yasmin and/or Yaz is significantly higher compared to the risk of developing stroke, deep vein thrombosis, pulmonary embolism, heart attack, gall bladder disease liver failure, kidney failure, severe anxiety, depression or sudden death associated with the use of second generation oral contraceptives;
- 16.9 Bayer did not provide adequate safety data to Health Canada with respect to Yasmin and Yaz. Bayer knew or should have known that Yasmin and Yaz were unsafe, defective, unreasonably dangerous, and not fit for their intended purpose;
- 16.10 At all material times, Bayer, through its servants and agents, negligently and/or carelessly marketed, distributed and/or sold Yasmin and Yaz without adequate warnings of the products' serious side effects and unreasonably dangerous risks;
17. In addition, Bayer marketed Yasmin and Yaz as providing the same efficacy as other birth control pills in preventing pregnancy, but with additional benefits;
18. Bayer promoted Yaz as an oral contraceptive, which also reduced menstrual symptoms such as headaches, cramps and breast tenderness. In addition, Yaz is promoted as treating acne and counteracting water retention, resulting in less bloating;
19. [...];

- 19.1 The Food and Drug Association (“FDA”) in the United States sent Bayer warning letters regarding their aggressive and controversial marketing efforts. Bayer has been warned at least three (3) times by the FDA, in 2003, 2008 and 2009, for misleading the public through the use of ads which overstate the efficacy of Yasmin and Yaz, and minimize serious risks associated with the drugs. Most recently, the FDA issued Bayer a warning letter for overstating Yaz’ ability to improve womens’ moods and clear up acne in television commercial advertisements. In addition, the FDA required Bayer to run a multi-million dollar television advertisement campaign to correct these misleading claims, as well as disclose the risks of hyperkalemia and other health problems associated with Yaz use. The FDA also directed Bayer to address false claims that Yasmin and Yaz were approved to treat Premenstrual Syndrome and all forms of acne, the whole as appears from the Food and Drug Administration letter dated March 26<sup>th</sup>, 2009, a copy of which is produced herewith as **Exhibit P-7**;
- 19.2 A Bayer press release dated January 20<sup>th</sup>, 2009, issued in Canada, which targeted "Gen Yers", states that Yaz may help reduce the symptoms experienced around the time of their period, although Yaz is not indicated for that use and has not been shown to be effective for that use. The press release includes a quote from a family physician stating “The availability of this new low-dose pill provides women with the benefits of reduced menstrual symptoms.” Similar to the advertising in the U.S. that the FDA took issue with, the Canadian press release also states that Yaz treats acne, but does not specify the type of acne it is indicated to treat. The press release also states that Yaz was found to be safe and well tolerated without warning of the increased risks associated with Yaz use compared to second generation oral contraceptives, the whole as appears from the Bayer press release dated January 20<sup>th</sup>, 2009, a copy of which is produced herewith as **Exhibit P-8**;
- 19.3 On March 26<sup>th</sup>, 2010, Bayer announced it would be updating the Yasmin label in the European Union to include the results of recent epidemiological studies with respect to venous thromboembolism, the whole as appears from the Bayer press release dated March 26<sup>th</sup>, 2010, a copy of which is produced herewith as **Exhibit P-9**;
- 19.4 On April 7<sup>th</sup>, 2010, the FDA approved new label changes for Yasmin and Yaz in the United States with respect to the risk of blood clots, the whole as appears from the Bayer letter and labels of Yasmin and Yaz, a copy of which is produced herewith as **Exhibit P-10**;
- 19.5 In Bayer’s Interim Report First Quarter of 2015, it is stated that as of April 2015, there were about 4,600 pending lawsuits and claims in the United States, excluding claims already settled, the total of which is not indicated, alleging personal injuries, some fatal, related to the use of

Yasmin and Yaz, the whole as appears from the Interim Report First Quarter of 2015 dated April 27<sup>th</sup>, 2015, a copy of which is produced herewith as **Exhibit P-11**;

19.6 On May 17<sup>th</sup>, 2011, a research paper published in the Canadian Medical Association Journal concluded that women using oral contraceptives containing drospirenone had a significantly increased risk of gallbladder disease, the whole as appears from the research paper published in the Canadian Medical Association Journal dated May 17<sup>th</sup>, 2011, a copy of which is produced herewith as **Exhibit P-12**;

19.7 On October 18<sup>th</sup>, 2012, an article published on the Science Daily web site referred to a Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research which found an increased risk of arterial thrombotic events associated with drospirenone-containing birth control pills, the whole as appears from the Science Daily article dated October 18<sup>th</sup>, 2012, a copy of which is produced herewith as **Exhibit P-13**;

20. In view of the foregoing, Bayer has:

- a) misrepresented information concerning the safety and efficacy of Yasmin and Yaz to the medical community and the public; and
- b) failed to provide adequate warning to the medical community and the public about Yasmin and Yaz's increased risk of serious adverse events, including deep vein thrombosis, blood clots, pulmonary embolism, heart attacks, stroke, gallbladder problems and infections, liver failure, kidney failure, severe anxiety, depression, and sudden death;

## II. FACTS GIVING RISE TO AN INDIVIDUAL ACTION BY THE PLAINTIFFS

21.[...];

22.[...];

23.[...];

24.[...];

25.[...];

26.[...];

27.[...];

28.[...];

29.[...];

30.[...];

31.[...];

32.[...];

33.[...];

### **Plaintiff Janie Guindon**

33.1 On or about August 1<sup>st</sup>, 2009, Plaintiff Janie Guindon began using the oral contraceptive Yaz;

33.2 Plaintiff Janie Guindon was 22 years of age when she began using the oral contraceptive Yaz;

33.3 Plaintiff Janie Guindon used the oral contraceptive Yaz in accordance with the manner it was intended to be used;

33.4 Shortly after her first use of the oral contraceptive Yaz, on or about October 14<sup>th</sup> 2009, Plaintiff was told she had developed gallstones;

33.5 On or about November 14<sup>th</sup>, 2009, Plaintiff Janie Guindon had her gallbladder removed;

33.6 On or about December 30<sup>th</sup>, 2009, Plaintiff Janie Guindon suffered from deep vein thrombosis;

33.7 On or about January 1<sup>st</sup>, 2010, Plaintiff Janie Guindon suffered from multiple pulmonary embolism;

33.8 On or about January 1<sup>st</sup>, 2010, Plaintiff Janie Guindon stopped taking Yaz;

33.9 Plaintiff Janie Guindon was in good health prior to her use of Yaz;

33.10 In the period before and during the use of Yaz by the Plaintiff Janie Guindon, she received no or inadequate warnings about the increased risk of developing stroke, deep vein thrombosis, pulmonary embolism, heart attack, or gall bladder disease and/or removal associated with Yaz use as compared to the use of second generation oral contraceptives;

- 33.11 Plaintiff Janie Guindon would not have taken Yaz if Bayer had properly disclosed the true risks and benefits of taking this medication;
- 33.12 Plaintiff's damages are a direct and proximate result of her use of the drug Yaz, Bayer's negligence and/or fault and/or lack of adequate warnings, and Bayer's misrepresentations as to its efficacy;
- 33.13 In consequence of the foregoing, Plaintiff Janie Guindon is justified in claiming damages;

**Plaintiffs Geneviève Gladu and Julien Leboeuf**

- 33.14 Plaintiff Geneviève Gladu was prescribed the oral contraceptive Yasmin shortly after it was approved by health Canada in 2004;
- 33.15 Plaintiff Geneviève Gladu used the oral contraceptive Yasmin until June of 2009;
- 33.16 Plaintiff Geneviève Gladu used Yasmin in accordance with the manner it was intended to be used;
- 33.17 On or about June 2009, Plaintiff Geneviève Gladu experienced abdominal pains;
- 33.18 Between June 7<sup>th</sup>, 2009 and July 7<sup>th</sup>, 2009, when she was 30 years of age, Plaintiff Geneviève Gladu was hospitalized for gallstones, gallbladder removed, pancreatitis and pulmonary embolism;
- 33.19 On or about June 7<sup>th</sup> 2009, Plaintiff Geneviève Gladu stopped taking Yasmin;
- 33.20 Plaintiff Geneviève Gladu was in excellent health prior to her use of Yasmin;
- 33.21 In the period before and during the use of Yasmin by the Plaintiff Geneviève Gladu, she received no or inadequate warnings about the increased risk of developing stroke, deep vein thrombosis, pulmonary embolism, heart attack, or gall bladder disease and/or removal associated with Yasmin use as compared to use of second generation oral contraceptives;
- 33.22 Plaintiff Geneviève Gladu would not have taken Yasmin if Bayer had properly disclosed the true risks and benefits of taking this medication;

33.23 Plaintiff's damages are a direct and proximate result of her use of the drug Yasmin, Bayer's negligence and/or fault and/or lack of adequate warnings, and Bayer's misrepresentations as to its efficacy;

33.24 In consequence of the foregoing, Plaintiff Geneviève Gladu is justified in claiming damages;

33.24.1. Plaintiff Julien Leboeuf has been the partner of Plaintiff Geneviève Gladu for the past ten years;

33.24.2. Plaintiffs Julien Leboeuf and Geneviève Gladu have two children;

33.24.3. Following the hospitalization of Plaintiff Geneviève Gladu in 2009, as described above, Plaintiff Julien Leboeuf suffered damages such as stress, fear of losing his partner and worry about the short and long term health of his partner;

[...]

33.25 [...];

33.26 [...];

33.27 [...];

33.28 [...];

33.29 [...];

33.30 [...];

33.31 [...];

33.32 [...];

33.33 [...];

33.34 [...];

### **III. FACTS GIVING RISE TO AN INDIVIDUAL ACTION BY EACH OF THE MEMBERS OF THE GROUP**

34. Every member of the class has either ingested and/or purchased Yaz and/or Yasmin or is the successor, family member, assign, and/or dependant of a person who purchased and/or ingested one of the aforementioned drugs;

35. The class members' damages would not have occurred but for the acts and/or omissions and/or fault of Bayer in failing to ensure that the drugs Yaz and Yasmin were safe for use, for failing to provide adequate warning of the risks associated with using them, and for over-promoting (and misrepresenting) their efficacy;
36. In consequence of the foregoing, each member of the class is justified in claiming at least one or more of the following as damages:
- a. physical and mental injuries, including pain, suffering, anxiety, fear, loss of quality and enjoyment of life, and increased risk of health problems;
  - b. out-of-pocket expenses incurred or to be incurred, including those connected with hospital stays, medical treatment, life care, medications, medical monitoring services, and the diagnosis and treatment of Yaz and Yasmin side effect services;
  - c. loss of income and loss of future income;
  - d. refund of the purchase price of Yaz and Yasmin or alternately, the incremental costs of Yaz and Yasmin as paid for by class members;
  - e. disgorgement of all profits earned by Bayer from the sale of the drugs Yaz and Yasmin;
  - f. punitive damages;
37. As a direct result of the Bayer's conduct and/or fault, the users' family members, and dependants have, had, and/or will suffer damages and loss, including:
- a. out of pocket expenses, including paying or providing nursing, housekeeping and other services;
  - b. loss of income and loss of future income;
  - c. loss of support, guidance, care, consortium, and companionship that they might reasonably have expected to receive if the injuries had not occurred;
38. [...];
39. All of these damages to the class members are a direct and proximate result of their use of the drug Yaz and/or Yasmin, Bayer's negligence and/or fault and/or lack of adequate warnings, and Bayer's misrepresentations as to its efficacy;



#### IV. CONDITIONS REQUIRED TO INSTITUTE A CLASS ACTION

**A) The composition of the class renders the application of Articles 59 or 67 C.C.P. difficult or impractical**

40. Plaintiffs are unaware of the specific number of persons who took and/or purchased these drugs, however, it is safe to estimate that it is in the tens of thousands (if not hundreds of thousands);
41. Class members are numerous and are scattered across the entire province;
42. Plaintiffs have no way of knowing the names and addresses of potential class members due to the confidential nature of medical and pharmacy records;
43. In addition, given the costs and risks inherent in an action before the courts, many people will hesitate to institute an individual action against Bayer. Even if the class members themselves could afford such individual litigation, the court system could not as it would be overloaded. Further, individual litigation of the factual and legal issues raised by the conduct of Bayer would increase delay and expense to all parties and to the court system;
44. Also, a multitude of actions instituted in different judicial districts, risks having contradictory judgements on questions of fact and law that are similar or related to all members of the class;
45. These facts demonstrate that it would be impractical, if not impossible, to contact each and every member of the class to obtain mandates and to join them in one action;
46. In these circumstances, a class action is the only appropriate procedure for all of the members of the class to effectively pursue their respective rights and have access to justice;

**B) The questions of fact and law which are identical, similar, or related with respect to each of the class members with regard to Bayer and that which the Plaintiffs wish to have adjudicated upon by this class action**

47. Individual questions, if any, pale by comparison to the numerous common questions that predominate;
48. The damages sustained by the class members flow, in each instance, from a common nucleus of operative facts, namely, Bayer's misconduct;

49. The recourses of the members raise identical, similar or related questions of fact or law, namely:

- a. Do Yaz and Yasmin cause, exacerbate, or contribute to serious adverse events, including deep vein thrombosis, blood clots, pulmonary embolism, heart attacks, stroke, gallbladder problems and infections, liver failure, kidney failure, severe anxiety, depression, and sudden death?
- b. Was Bayer negligent and/or did it commit a fault and/or did it fail in its duty of safety, duty of care, and/or duty to inform imposed upon it as manufacturer, distributor and/or seller of Yaz and Yasmin?
- c. Do Yaz and Yasmin possess a superior efficacy over other contraceptives available on the market?
- d. Did Bayer knowingly, recklessly or negligently breach a duty to warn class members and/or their physicians of the risks of harm from the use of Yaz and Yasmin?
- e. Did Bayer knowingly, recklessly or negligently misrepresent to class members and/or their physicians the risks and benefits from the use of Yaz and Yasmin?
- f. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin were safe?
- g. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin had a superior efficacy over other contraceptions?
- h. In the affirmative to any of the above questions, did Bayer conduct engage its liability towards the members of the class?
- i. If the responsibility of the Bayer is established, what is the nature and the extent of damages and other remedies to which the members of the class can claim?
- j. Are members of the class entitled to bodily, moral, and material damages?
- k. Are members of the class entitled to recover the medical costs incurred in the screening, diagnosis and treatment of medical conditions caused by taking Yaz and Yasmin?

- l. Are the members of the class entitled to recover as damages an amount equal to the purchase price of Yaz and Yasmin or any part of the purchase price?
- m. Should Bayer be ordered to disgorge all or part of its ill-gotten profits received from the sale of Yaz and Yasmin?
- n. Are members of the class entitled to aggravated or punitive damages?

50. The interests of justice favour that this motion be granted in accordance with its conclusions;

## V. NATURE OF THE ACTION AND CONCLUSIONS SOUGHT

51. The action that Plaintiffs wish to institute on behalf of the members of the class is an action in damages;

52. The conclusions that Plaintiffs wish to introduce by way of a motion to institute proceedings are:

**GRANT** the class action of Plaintiffs and each of the members of the class;

**DECLARE** the Defendant liable for the damages suffered by the Plaintiffs and each of the members of the class;

**CONDEMN** the Defendant to pay to each member of the class a sum to be determined in compensation of the damages suffered, and **ORDER** collective recovery of these sums;

**CONDEMN** the Defendant to reimburse to each of the members of the class, the purchase price of the product, and **ORDER** collective recovery of these sums;

**CONDEMN** the Defendant to pay to each of the members of the class, punitive damages, and **ORDER** collective recovery of these sums;

**RESERVE** the right of each of the members of the class to claim future damages related to the use of Yaz and Yasmin;

**CONDEMN** the Defendant to pay interest and additional indemnity on the above sums according to law from the date of service of the motion to authorize a class action;

**ORDER** the Defendant to deposit in the office of this court the totality of the sums which forms part of the collective recovery, with interest and costs;

**ORDER** that the claims of individual class members be the object of collective liquidation if the proof permits and alternately, by individual liquidation;

**CONDEMN** the Defendant to bear the costs of the present action including expert, notice fees and the fees relating to administering the plan of distribution of the recovery in this action;

**RENDER** any other order that this Honourable court shall determine and that is in the interest of the members of the class;

**A) The Plaintiffs request the status of representative of the Class**

53. Plaintiffs are members of the class;
54. Plaintiffs are ready and available to manage and direct the present action in the interest of the members of the class that they wish to represent and are determined to lead the present dossier until a final resolution of the matter, the whole for the benefit of the class, as well as, to dedicate the time necessary for the present action before the Courts of Quebec and the *Fonds d'aide aux recours collectifs*, as the case may be, and to collaborate with their attorneys;
55. Plaintiffs have the capacity and interest to fairly and adequately protect and represent the interest of the members of the class;
56. Plaintiffs have given the mandate to their attorneys to obtain all relevant information with respect to the present action and intend to keep informed of all developments;
57. Plaintiffs, with the assistance of their attorneys, are ready and available to dedicate the time necessary for this action and to collaborate with other members of the class and to keep them informed;
58. Plaintiffs are in good faith and have instituted this action for the sole goal of having their rights, as well as the rights of other class members recognized and protected so that they may be compensated for the damages that they have suffered as a consequence of the Bayer's conduct;
59. Plaintiffs understand the nature of the action;
60. The interests of the Plaintiffs are not antagonistic to those of other members of the class;

**B) The Plaintiff suggests that this class action be exercised before the Superior Court of justice in the district of Montreal**

61. A great number of the members of the class reside in the judicial district of Montreal and in the appeal district of Montreal;

62. Bayer has its principal place of business in the judicial district of Montreal;

63. [...];

64. The Plaintiffs' attorneys practice their profession in the judicial district of Montreal;

65. The present motion is well founded in fact and in law.

**FOR THESE REASONS, MAY IT PLEASE THE COURT:**

**GRANT** the present motion;

**AUTHORIZE** the bringing of a class action in the form of a motion to institute proceedings in damages;

**ASCRIBE** the Plaintiffs the status of representatives of the persons included in the class herein described as:

«All persons residing in Quebec who were prescribed and ingested the drugs YASMIN and/or YAZ, from the respective introductions of these drugs into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of YAZ) and the date of November 30, 2011 and their successors, assigns, family members, and dependants or any other group to be determined by the Court.»

**IDENTIFY** the principle questions of fact and law to be treated collectively as the following:

- a. Do Yaz and Yasmin cause, exacerbate, or contribute to serious adverse events, including deep vein thrombosis, blood clots, pulmonary embolism, heart attacks, stroke, gallbladder problems and infections, liver failure, kidney failure, severe anxiety, depression, and sudden death?
- b. Was Bayer negligent and/or did it commit a fault and/or did it fail in its duty of safety, duty of care, and/or duty to inform imposed upon it as manufacturer, distributor and/or seller of Yaz and Yasmin?

- c. Do Yaz and Yasmin possess a superior efficacy over other contraceptives available on the market?
- d. Did Bayer knowingly, recklessly or negligently breach a duty to warn class members and/or their physicians of the risks of harm from the use of Yaz and Yasmin?
- e. Did Bayer knowingly, recklessly or negligently misrepresent to class members and/or their physicians the risks and benefits from the use of Yaz and Yasmin?
- f. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin were safe?
- g. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin had a superior efficacy over other contraceptions?
- h. In the affirmative to any of the above questions, did Bayer conduct engage its liability towards the members of the class?
- i. If the responsibility of the Bayer is established, what is the nature and the extent of damages and other remedies to which the members of the class can claim?
- j. Are members of the class entitled to bodily, moral, and material damages?
- k. Are members of the class entitled to recover the medical costs incurred in the screening, diagnosis and treatment of medical conditions caused by taking Yaz and Yasmin?
- l. Are the members of the class entitled to recover as damages an amount equal to the purchase price of Yaz and Yasmin or any part of the purchase price?
- m. Should Bayer be ordered to disgorge all or part of its ill-gotten profits received from the sale of Yaz and Yasmin?
- n. Are members of the class entitled to aggravated or punitive damages?

**IDENTIFY** the conclusions sought by the class action to be instituted as being the following:

**GRANT** the class action of Plaintiffs and each of the members of the class;

**DECLARE** the Defendant liable for the damages suffered by the PLAINTIFFS and each of the members of the class;

**CONDEMN** the Defendant to pay to each member of the class a sum to be determined in compensation of the damages suffered, and **ORDER** collective recovery of these sums;

**CONDEMN** the Defendant to reimburse to each of the members of the class, the purchase price of the product, and **ORDER** collective recovery of these sums;

**CONDEMN** the Defendant to pay to each of the members of the class, punitive damages, and **ORDER** collective recovery of these sums;

**RESERVE** the right of each of the members of the class to claim future damages related to the use of Yaz and Yasmin;

**CONDEMN** the Defendant to pay interest and additional indemnity on the above sums according to law from the date of service of the motion to authorize a class action;

**ORDER** the Defendant to deposit in the office of this court the totality of the sums which forms part of the collective recovery, with interest and costs;

**ORDER** that the claims of individual class members be the object of collective liquidation if the proof permits and alternately, by individual liquidation;

**CONDEMN** the Defendant to bear the costs of the present action including expert, notice fees and the fees relating to administering the plan of distribution of the recovery in this action;

**RENDER** any other order that this Honourable court shall determine and that is in the interest of the members of the class;

**DECLARE** that all members of the class that have not requested their exclusion, be bound by any judgement to be rendered on the class action to be instituted in the manner provided for by law;

**FIX** the delay of exclusion at thirty (30) days from the date of the publication of the notice to the members, date upon which the members of the class that have not exercised their means of exclusion will be bound by any judgement to be rendered herein;



**ORDER** the publication of a notice to the members of the group in accordance with article 1006 C.C.P. within sixty (60) days from the judgement to be rendered herein in the JOURNAL DE QUÉBEC, the JOURNAL DE MONTRÉAL, LA PRESSE and the NATIONAL POST;

**ORDER** that said notice be available on the Bayer's website with a link stating "Notice to Yaz and Yasmin users";

**RENDER** any other order that this Honourable court shall determine and that is in the interest of the members of the class;

**THE WHOLE** with costs including publications fees.

Montreal, February 2<sup>nd</sup>, 2017

*Siskinds Desmeules, Avocats, S.E.N.C.R.L.*

Maître Samy Elnemr

samy.elnemr@siskindsdesmeules.com

SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L.

Attorneys for the Plaintiffs

480, Saint-Laurent

Bureau 501, Montréal, Québec H2Y 3Y7

Telephone : 514-849-1970

Fax : 514-849-7934

Notification: [notification@siskindsdesmeules.com](mailto:notification@siskindsdesmeules.com)

**NOTICE OF PRESENTATION**

TO: **Me Sylvie Rodrigue, Ad. E.**  
Société d'avocats Torys s.e.n.c.r.l.  
1 place Ville-Marie  
Suite 1919  
Montreal, Quebec  
H3B 2C3

Attorneys for the Defendant Bayer Inc.

**TAKE NOTICE** that the Plaintiffs' Motion will be presented for adjudication before The Honourable Justice Guylène Beaugé on a date and time to be determined by the Court at the Montréal Courthouse located at 1, Notre-Dame East, Montreal, Quebec, H2Y 1B6.

Montreal, February 2<sup>nd</sup>, 2017

*Siskinds, Desmeules, Avocats, S.E.N.C.R.L.*

Maître Samy Elnemr  
samy.elnemr@siskindsdesmeules.com  
SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L.  
Attorneys for the Plaintiffs  
480, Saint-Laurent  
Bureau 501, Montréal, Québec H2Y 3Y7  
Telephone : 514-849-1970  
Fax : 514-849-7934  
Notification: [notification@siskindsdesmeules.com](mailto:notification@siskindsdesmeules.com)

CANADA

(Class Action)  
SUPERIOR COURT

PROVINCE OF QUEBEC  
DISTRICT OF MONTREAL

NO: 500-06-000484-093

**JANIE GUINDON**

and

**GENEVIÈVE GLADU**

and

**JULIEN LEBOEUF**

Plaintiffs

v.

**BAYER INC.**

Defendant

---

**LIST OF EXHIBITS**

---

- EXHIBIT P-1:** Bayer's Information Sheet on the Registraire des entreprises du Québec;
- EXHIBIT P-2:** Yasmin Product Monographs;
- EXHIBIT P-3:** Yaz Product Monographs;
- EXHIBIT P-4:** British Medical Journal Article, dated April 13, 2002;
- EXHIBIT P-5:** British Medical Journal Paper, dated February 1, 2003;
- EXHIBIT P-6:** British Medical Journal Study;
- EXHIBIT P-7:** Food and Drug Administration letter, dated March 26, 2009;
- EXHIBIT P-8:** Bayer Press Release, dated January 20, 2009;
- EXHIBIT P-9:** Bayer Press Release, dated March 26, 2010;
-

- EXHIBIT P-10:** Bayer letter and labels of Yasmin and Yaz;
- EXHIBIT P-11:** Interim Report First Quarter of 2015, dated April 27, 2015;
- EXHIBIT P-12:** Research paper published in the Canadian Medical Association Journal, dated May 17, 2011;
- EXHIBIT P-13:** Science Daily article, dated October 18, 2012.

Montreal, February 2<sup>nd</sup>, 2017

*Siskinds, Desmeules, Avocats, S.E.N.C.R.L.*

Maître Samy Elnemr

samy.elnemr@siskindsdesmeules.com

SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L.

Attorneys for the Plaintiffs

480, Saint-Laurent

Bureau 501, Montréal, Québec H2Y 3Y7

Telephone : 514-849-1970

Fax : 514-849-7934

Notification: [notification@siskindsdesmeules.com](mailto:notification@siskindsdesmeules.com)

CANADA  
PROVINCE OF QUÉBEC  
DISTRICT OF MONTRÉAL

SUPERIOR COURT – CLASS ACTION  
NO: 500-06-000484-093

**JANIE GUINDON**

**ET AL.**

Plaintiffs

v.

**BAYER INC.**

Defendant

P

---

**RE-RE-AMENDED MOTION TO AUTHORIZE THE  
BRINGING OF A CLASS ACTION & TO ASCRIBE  
THE STATUS OF REPRESENTATIVES  
(Art. 1002 C.C.P. and following),  
NOTICE OF PRESENTATION, LIST OF EXHIBITS**

---

ORIGINAL

---

**BB-6852**  
**Me Sammy Elnemr**  
O/F : 67-095

**SISKINDS**  
MONTRÉAL

SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L.

480, Saint-Laurent, Suite 501  
Montréal, Québec H2Y 3Y7  
Tel. : (514) 849-1970  
Fax : (514) 849-7934  
[www.siskinds.com](http://www.siskinds.com)

1790316